Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 12;2(1):72-80.
doi: 10.3109/21556660.2013.794143. eCollection 2013.

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat

Affiliations

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat

Anthony Caggiano et al. J Drug Assess. .

Abstract

Background: Dalfampridine (4-aminopyridine; 4-AP) is a potassium channel blocker available in the United States to improve walking in patients with multiple sclerosis as demonstrated by an increase in walking speed. Its pharmacokinetics have been evaluated in human studies but its metabolites are not well characterized. This study characterizes the metabolic profile of dalfampridine in two animal species that were used to support nonclinical toxicology evaluation.

Methods: Metabolic profiling of single oral (14)C-4-AP doses was performed in 12 adult male Sprague-Dawley rats. Similarly, metabolic profiling was performed in beagle dogs in two studies that administered (14)C-4-AP by gastric intubation; the first study included six animals (three males, three females), and the second study included two animals (one male, one female). Blood and urine samples were evaluated using high performance liquid chromatography, thin layer chromatography, and radioanalysis (liquid scintillation counting), with further identification of components by gas chromatography/mass spectrometry.

Results: Five radioactive components, M1-M5, were detected in rat plasma, although most of the radioactivity corresponded with unchanged 4-AP. Based on Rf values, M1 and M2 coseparated with reference standards of 3-hydroxy-4-AP and 4-AP, respectively. Additionally, components M1, M2, and M3 coseparated with the same components isolated from the urine of a dog dosed with (14)C-4-AP and identified as 3-hydroxy-4-AP, 4-AP, and 3-hydroxy-4-AP sulfate, respectively; M4 and M5 could not be identified because of low concentrations. In dogs, most of the radioactivity was excreted within the first 24 hours as unchanged compound.

Conclusions: Following oral dosing, 4-AP was rapidly absorbed in rats and dogs, with rapid excretion and almost complete urinary recovery in dogs. The primary metabolites in both animal models were 3-hydroxy-4-AP and 3-hydroxy-4-AP sulfate. Systemic clearance not accounted for by renal excretion of 4-AP may occur by liver metabolism by hydroxylation of 4-AP to 3-hydroxy-4-AP followed by sulfate conjugation to 3-hydroxy-4-AP sulfate.

Keywords: 4-aminopyridine; Dalfampridine; Dog; Metabolites; Preclinical models; Rat.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mean concentration of radioactivity in portal and systemic rat plasma after oral administration of 4.6 mg/kg 14C-4-aminopyridine to male rats.
Figure 2.
Figure 2.
Mean proportions of radioactive components M2 and M3 in portal and systemic plasma, determined by thin layer chromatography and expressed as percentage of extract radioactivity, after oral administration of 4.6 mg/kg 14C-4-aminopyridine to male rats. M2 corresponded to unchanged 4-aminopyridine and M3 to 3-hydroxy-4-aminopyridine sulfate.
Figure 3.
Figure 3.
Mean proportions of radioactive components in urine determined by high performance liquid chromatography, expressed as percentage of sample radioactivity, after oral administration of 1 mg/kg 14C-4-aminopyridine to male (n = 3) and female (n = 3) beagle dogs. M1, M2, and M3 were identified as 3-hydroxy-4-aminopyridine, unchanged 4-aminopyridine, and 3-hydroxy-4-aminopyridine sulfate, respectively.
Figure 4.
Figure 4.
Concentrations of radioactivity in canine plasma after oral administration of 1 mg/kg 14C-4-aminopyridine to a male and female beagle dog.
Figure 5.
Figure 5.
Mean proportions of radioactive components in urine determined by thin layer chromatography (A) and high performance liquid chromatography (B) expressed as percentage of sample radioactivity, after oral administration of 1 mg/kg 14C-4-aminopyridine to a male and female beagle dog. M1, M2, and M3 were identified as 3-hydroxy-4-aminopyridine, unchanged 4-aminopyridine, and 3-hydroxy-4-aminopyridine sulfate, respectively.
Figure 6.
Figure 6.
Mass spectra identification of components M1 and M2 isolated from dog urine in the second canine study. Identification of M1 (A) was based on authentic 3-hydroxy-4-aminopyridine (B) and M2 (C) was based on authentic 4-aminopyridine (D). Samples were derivatized prior to gas chromatography mass spectroscopy as stated in Methods.
Figure 7.
Figure 7.
Mass spectra evaluation of M3 isolated from dog urine in the second canine study. Precursor electrospray ionization spectrum (A). Product ion scan of m/z 189 ion of component M3 (B).

Similar articles

Cited by

References

    1. Ampyra® (dalfampridine) extended release tablets [package insert]. Ardsley, NY, USA: Acorda Therapeutics Inc., 2011
    1. Goodman AD Brown TR Krupp L et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8 - PubMed
    1. Goodman AD Brown TR Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502 - PubMed
    1. Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 2011;27:1415-23 - PubMed
    1. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-61 - PubMed

LinkOut - more resources